drugset / Trial / NCT02531724

Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery

NCT02531724

Phase 4 Completed 30 enrolled Sahlgrenska University Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Acute kidney injury (AKI) is a common complication after cardiac surgery. Mismatch in renal oxygen demand-supply may be an important pathogenetic factor. Levosimendan has been shown to improve renal blood flow, glomerular filtration rate and renal oxygenation in healthy controls after cardiac surgery. In order to investigate the effect of levosimendan in patients with AKI after cardiac surgery, the investigators plan a randomized placebo controlled trial. 30 patients will receive levosimendan or placebo. Renal blood flow and filtration fraction will be measured using infusion clearance technique of para-aminohippuric acid and Chromium ethylenediaminetetraacetic acid (Cr-EDTA) respectively.

Timeline

Start
2015-09
Primary completion
2020-12
Completion
2020-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Levosimendan Other / unclassified 0.1 ug/kg

Indications